Clinical Trial Update: A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC). [Phase 3]

View source ↗

Summary

A Phase 3, placebo-controlled trial of sorafenib in predominantly non-squamous non-small cell lung cancer after third or fourth line therapy has completed and p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Nexavar (Sorafenib)

Snippet

Sponsor: Bayer | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED | Results posted: 2013-07-30